Rationales and uncertainties for aspirin use in COVID-19: a narrative review - PMC Back to
Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …

Antithrombotic therapy is a key element of secondary prevention in patients who have had
an ischaemic stroke or transient ischaemic attack. However, its use in clinical practice is not …

Antiplatelet agents are a cornerstone of therapy for patients with atherosclerotic vascular
disease. There is presently a lack of comprehensive guidelines focusing on the use of …

Background and purpose Guidelines recommend that patients with high-risk TIAs and minor
strokes presenting within 1–3 days from onset should be offered dual antiplatelet therapy …

Introduction Blunt cerebrovascular injury (BCVI) occurs in 1-3% of blunt traumas and is
associated with stroke, disability, and mortality if unrecognized and untreated. Early …

Background Three landmark trials on the use of acetylsalicylic acid (ASA) for primary
prevention of cardiovascular disease (CVD) were published in 2018. Since then, major …

Cardiovascular disease (CVD) remains the leading cause of death globally and an ageing
world population is expected to increase the burden of CVD further. Among older adults …

Objectives Epistaxis is the most common otolaryngological emergency and one-third of
epistaxis patients regularly take low-dose acetylsalicylic acid (ASA) for the prevention of …

Background and purpose Guidelines recommend patients with high-risk TIAs and minor
stroke presenting within 1-3 days from onset be offered dual antiplatelet therapy (DAPT) …

Background & Aims: It is unknown if the COVID-19 pandemic and public health measures
had an immediate impact on stroke subtypes and etiologies in patients not infected with …